Association Between Body Mass Index and Cardiac Dysfunction During Human Epidermal Growth Factor Receptor 2 Inhibitor Therapy for Breast Cancer
Background: The administration of human epidermal growth factor receptor 2 inhibitors (HER2i) has improved the survival of patients with breast cancer; however, cancer therapy-related cardiac dysfunction (CTRCD) has been reported as an adverse effect. In this study we evaluated the incidence of CTRCD associated with HER2i treatment and explored risk factors for a decrease in left ventricular function.
Authors
- Taketsugu Tsuchiya (ORCID: https://orcid.org/0000-0001-8152-7039)
- Y. Saeki
- Masafumi Inokuchi (ORCID: https://orcid.org/0000-0001-8886-9517)
- Yasuhito Ishigaki (ORCID: https://orcid.org/0000-0003-1012-8430)
- Miharu Masaki
- Minoru Wakasa
- Masaru Sakurai (ORCID: https://orcid.org/0000-0002-4929-3225)
- Kayoko Yamaguchi
- Tetsuhiro Horie
Institutions
- Kanazawa Medical University (JP)
Publication Details
- Journal
- Circulation Reports
- Published
- 2026-07-23
- DOI
- https://doi.org/10.1253/circrep.cr-25-0339
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00